Comparison of diagnostic value of 68 Ga-DOTATOC PET/MRI and standalone MRI for the detection of intracranial meningiomas.
Adult
Aged
Aged, 80 and over
Contrast Media
Female
Humans
Magnetic Resonance Imaging
/ methods
Male
Meningeal Neoplasms
/ diagnosis
Meningioma
/ diagnosis
Middle Aged
Octreotide
/ analogs & derivatives
Organometallic Compounds
/ metabolism
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 04 2021
27 04 2021
Historique:
received:
17
07
2020
accepted:
01
04
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
15
10
2021
Statut:
epublish
Résumé
To evaluate the diagnostic performance of magnetic resonance imaging (MRI) alone in comparison to positron emission tomography/ magnetic resonance imaging (PET/MRI) in patients with meningiomas. 57 patients with a total of 112 meningiomas of the brain were included. PET/MRI, including a fully diagnostic contrast enhanced MRI and PET, were acquired. PET/MRI was used as reference standard. The size and location of meningiomas was recorded. Likelihood-ratio chi-square tests were used to calculate p-values within logistic regression in order to compare different models. A multi-level logistic regression was applied to comply the hierarchical data structure. Multi-level regression adjusts for clustering in data was performed. The majority (n = 103) of meningiomas could be identified based on standard MRI sequences compared to PET/MRI. MRI alone achieved a sensitivity of 95% (95% CI 0.78, 0.99) and specificity of 88% (95% CI 0.58, 0.98). Based on intensity of contrast medium uptake, 97 meningiomas could be diagnosed with intense uptake (93.75%). Sensitivity was lowest with 74% for meningiomas < 0.5 cm
Identifiants
pubmed: 33907204
doi: 10.1038/s41598-021-87866-9
pii: 10.1038/s41598-021-87866-9
pmc: PMC8079685
doi:
Substances chimiques
Contrast Media
0
Ga(III)-DOTATOC
0
Organometallic Compounds
0
Radiopharmaceuticals
0
Octreotide
RWM8CCW8GP
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9064Références
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1391-1399
pubmed: 31758226
Orbit. 2015 Feb;34(1):16-22
pubmed: 25264824
Neuro Oncol. 2017 Nov 29;19(12):1576-1587
pubmed: 28605532
Neurosurg Focus. 2019 Jun 1;46(6):E9
pubmed: 31153151
J Neurosurg. 2010 Nov;113(5):1036-42
pubmed: 20433281
J Nucl Med. 2015 Mar;56(3):347-53
pubmed: 25635133
Q J Nucl Med Mol Imaging. 2018 Sep;62(3):239-253
pubmed: 29696946
J Neurooncol. 1998 Apr;37(2):177-88
pubmed: 9524097
Neuro Oncol. 2019 Jan 14;21(Suppl 1):i44-i61
pubmed: 30649491
Neurosurg Clin N Am. 2016 Apr;27(2):137-43
pubmed: 27012378
Radiology. 2012 Dec;265(3):910-6
pubmed: 23093680
Lancet Oncol. 2008 May;9(5):453-61
pubmed: 18452856
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
Neuro Oncol. 2015 Feb;17(2):312-9
pubmed: 25008094
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):537-538
pubmed: 30552446
Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1409-15
pubmed: 22669255
J Clin Epidemiol. 1992 Jan;45(1):1-7
pubmed: 1738006
Lancet Neurol. 2010 Sep;9(9):906-20
pubmed: 20705518
Nat Rev Clin Oncol. 2009 Nov;6(11):648-57
pubmed: 19806145
J Clin Oncol. 2001 Aug 1;19(15):3547-53
pubmed: 11481362
J Neurosurg. 2012 Dec;117(6):999-1006
pubmed: 23061394
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):222-7
pubmed: 16488553
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):310-8
pubmed: 19763565
J Nucl Med. 2001 Jul;42(7):1053-6
pubmed: 11438627
AJNR Am J Neuroradiol. 2011 Dec;32(11):1978-85
pubmed: 21393407
Eur J Nucl Med. 2001 Apr;28(4):426-34
pubmed: 11357492
EJNMMI Phys. 2016 Dec;3(1):8
pubmed: 27271304
Radiology. 2000 Nov;217(2):377-84
pubmed: 11058631
Nat Rev Neurol. 2017 May;13(5):279-289
pubmed: 28387340
J Nucl Med. 2015 Jan;56(1):3-8
pubmed: 25500828